Sugi Predict

Sugi Predict / Compounds / SCHEMBL4085175

SCHEMBL4085175

SCHEMBL4085175

CS(=O)(=O)c1cccc(NC(=O)NC(c2ccc(C(=O)Nc3nn[nH]n3)cc2)c2ccc(C3CCCCC3)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 6/20 0.43
▸ LMNA P02545 2/20 0.43
▸ NAMPT P43490 1/20 0.39
▸ CCKBR P32239 2/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ GIPR P48546 2/20 0.37
▸ ADCY6 O43306 1/20 0.37
▸ ADCY3 O60266 1/20 0.37
▸ ADCY9 O60503 1/20 0.37
▸ ADCY5 O95622 1/20 0.37
▸ ADCY8 P40145 1/20 0.37
▸ ADCY7 P51828 1/20 0.37
▸ ADCY2 Q08462 1/20 0.37
▸ ADCY1 Q08828 1/20 0.37
▸ ADCY4 Q8NFM4 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HDAC3 O15379 1/20 0.36
▸ HDAC11 Q96DB2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4092326 0.94 LMNA (0.45) GCGRLMNANAMPTGIPRADCY6
SCHEMBL4092780 0.92 GCGR (0.46) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4091977 0.92 GCGR (0.44) GCGRLMNAALDH1A1MEN1KMT2A
SCHEMBL4088312 0.92 LMNA (0.42) GCGRLMNANAMPTCCKBRALDH1A1
SCHEMBL4095065 0.90 GCGR (0.44) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4091639 0.90 LMNA (0.56) LMNAALDH1A1MEN1KMT2AGAA
SCHEMBL4092648 0.90 GCGR (0.43) GCGRLMNANAMPTCCKBRALDH1A1
SCHEMBL4087662 0.89 GCGR (0.46) GCGRLMNANAMPTCCKBRALDH1A1
SCHEMBL4092494 0.89 GCGR (0.45) GCGRLMNANAMPTCCKBRGIPR
SCHEMBL4085772 0.89 MAPT (0.45) GCGRLMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885LMNA 3643/4885NAMPT 1813/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885LMNA 3643/4885NAMPT 1813/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885LMNA 3643/4885NAMPT 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.